Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

An 18 Percent Solution? Lilly And Daiichi Bet On A Premium Price For Effient Over Plavix

This article was originally published in The Pink Sheet Daily

Executive Summary

Wall Street analysts fret over a black box warning and see a slow uptake for Effient, but still expect drug to reach blockbuster status.

You may also be interested in...



Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch

Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.

Lilly Will Play The Metabolism Card In Effient's Imminent U.S. Launch

Meanwhile, second-quarter sales of the oral platelet inhibitor outside the U.S. prove to be…thin.

Effient Approval Shows Mark Of FDA Controls

Postmarketing trials offer opportunity to investigate a possible means to control the bleeding caused by prasugrel, but REMS includes messaging aimed at limited off-label use.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069698

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel